Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 18/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21589694 | 1.00 | SLC10A2 (0.34) | SLC10A2NR1H4LMNAPLA2G1BTSHR | |
| SCHEMBL29462827 | 1.00 | SLC10A2 (0.34) | SLC10A2NR1H4LMNAPLA2G1BTSHR | |
| SCHEMBL21589695 | 1.00 | SLC10A2 (0.34) | SLC10A2NR1H4LMNAPLA2G1BTSHR | |
| SCHEMBL22476189 | 0.92 | NR1H4 (0.32) | NR1H4LMNAPLA2G1BTSHRKMT2A | |
| SCHEMBL29462804 | 0.91 | SLC10A2 (0.36) | SLC10A2NR1H4LMNAPLA2G1BTSHR | |
| SCHEMBL21589616 | 0.91 | SLC10A2 (0.36) | SLC10A2NR1H4LMNAPLA2G1BTSHR | |
| SCHEMBL22502861 | 0.90 | SLC10A2 (0.37) | SLC10A2NR1H4 | |
| SCHEMBL21586020 | 0.89 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL21586019 | 0.89 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL21589715 | 0.89 | SLC10A2 (0.34) | SLC10A2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802504-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-01-18 | — | — | EP | claimed |
| US-11306064-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2022-04-19 | — | — | US | claimed |
| CN-112449637-A | Benzothia (di) azepanes and their use as bile acid modulators | 阿尔比里奥公司 | 2021-03-05 | — | — | CN | claimed |
| US-20210017141-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-01-21 | — | — | US | claimed |
| US-10793534-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2020-10-06 | — | — | US | claimed |
| CN-112449637-B | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-3802504-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| EP-3802504-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| US-11306064-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2022-04-19 | — | — | US | disclosed |
| CN-112449637-A | Benzothia (di) azepanes and their use as bile acid modulators | 阿尔比里奥公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20210017141-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017141-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-01-21 | — | — | US | disclosed |
| US-10793534-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2020-10-06 | — | — | US | disclosed |
| US-10793534-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2020-10-06 | — | — | US | disclosed |
| WO-2019234077-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793534-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 7/4885LMNA 3539/4885 |
| US-11306064-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 7/4885LMNA 3539/4885 |
| US-20210017141-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 7/4885LMNA 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.